Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) in Patients With Metastatic or Locally Advanced Ovarian Cancer
Status: | Archived |
---|---|
Conditions: | Ovarian Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | October 2008 |
A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients
with metastatic or locally advanced platinum-resistant ovarian cancer.
Patients will be randomized 1:1 into one of two treatment arms. NKTR-102 will be
administered at a dose level of 145 mg/m2 in both arms. In Arm A, NKTR-102 will be given on
a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. Approximately 70
patients may be evaluated in this study with approximately 35 patients in each treatment
arm.
We found this trial at
5
sites
1309 North Flagler Drive
West Palm Beach, Florida 33401
West Palm Beach, Florida 33401
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)